Literature DB >> 7294162

Comparative study of eosinophil and neutrophil chemotaxis and enzyme release.

H Ogawa, S L Kunkel, J C Fantone, P A Ward.   

Abstract

It has been well documented that both natural and synthetic chemotactic peptides can induce lysosomal enzyme release from neutrophils treated with cytochalasin B. These same peptides are also potent inducers of unidirectional movement, as demonstrated by the chemotactic response in Boyden chambers. In this study, the ability of another family of leukocytes, eosinophils, to release lysosomal enzymes and exhibit a chemotactic response to both natural and synthetic chemotactic peptides was examined. A striking fundamental difference between neutrophil and eosinophil chemotaxis and enzyme release was shown using C5a, formyl met-leu-phe (FMLP), and ala-gly-ser-glu (AGSG) peptides. The 50% effective doses (ED50) for chemotactic responses to C5a, FMLP, or AGSG by neutrophils and eosinophils were 0.05 microgram/ml and 1.0 microgram/ml, 10(-12) M and 10(-10) M, and 10(-7) M and 10(-7) M, respectively. At the same concentrations, these peptides (C5a, f met-leu-phe, and ala-gly-ser-glu) induced the following release of glucosaminidase from neutrophils and eosinophils, respectively: 42% and 2%, 42% and 2%, and 29% and 2%. In striking contrast, immune complexes and opsonized zymosan particles induced the release of 39% and 42% of the total glucosaminidase from neutrophils, while eosinophils released 32% and 43% of the total glucosaminidase from immune complexes and opsonized zymosan particles, respectively. These data indicate fundamental differences between neutrophils and eosinophils in unidirectional movement induced by chemotactic factors and enzyme release mechanism(s).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7294162      PMCID: PMC1903875     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Eosinophils as mediators of antibody-dependent damage to schistosomula.

Authors:  A E Butterworth; R F Sturrock; V Houba; A A Mahmoud; A Sher; P H Rees
Journal:  Nature       Date:  1975-08-28       Impact factor: 49.962

2.  Studies in experimental eosinophilia. I. Repeated quantitation of peritoneal eosinophilia in guinea pigs by a method of peritoneal lavage.

Authors:  M LITT
Journal:  Blood       Date:  1960-09       Impact factor: 22.113

3.  Selective attraction of eosinophils and synergism between eosinophil chemotactic factor of anaphylaxis (ECF-A) and a fragment cleaved from the fifth component of complement (C5a).

Authors:  A B Kay; H S Shin; K F Austen
Journal:  Immunology       Date:  1973-06       Impact factor: 7.397

4.  Membrane protein alterations in the neutrophil in response to chemotactic factors.

Authors:  R S Thrall; S H Phan; H J Showell; D J Williams; J T O'Flaherty; P A Ward
Journal:  Mol Immunol       Date:  1980-02       Impact factor: 4.407

5.  Specific binding of synthetic chemotactic peptides to rabbit peritoneal neutrophils: effects on dissociability of bound peptide, receptor activity and subsequent biologic responsiveness (deactivation).

Authors:  G Vitkauskas; H J Showell; E L Becker
Journal:  Mol Immunol       Date:  1980-02       Impact factor: 4.407

6.  Biochemical quantitation of the chemotactic factor inactivator activity in human serum.

Authors:  J Fantone; R M Senior; D L Kreutzer; M Jones; P A Ward
Journal:  J Lab Clin Med       Date:  1979-01

7.  Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis.

Authors:  E J Goetzl; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

8.  The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils.

Authors:  H J Showell; R J Freer; S H Zigmond; E Schiffmann; S Aswanikumar; B Corcoran; E L Becker
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

9.  The selective eosinophil chemotactic activity of histamine.

Authors:  R A Clark; J I Gallin; A P Kaplan
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

10.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  6 in total

1.  The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo.

Authors:  L H Faccioli; S Nourshargh; R Moqbel; F M Williams; R Sehmi; A B Kay; T J Williams
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

2.  Alveolar macrophages and eicosanoids but not neutrophils, mediate bronchoconstriction induced by FMLP in the guinea-pig.

Authors:  M A Boukili; M F Bureau; A Lellouch-Tubiana; J Lefort; M T Simon; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

3.  Auto-antibody dependent activation of the autologous classical complement pathway by guinea-pig red cells treated with influenza virus or neuraminidase: in vitro and in vivo study.

Authors:  C R Lambre; M Thibon; S Le Maho; G Di Bella
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

4.  Effect of N-formylated methionyl-phenylalanine (FMP) and methionyl-leucyl-phenylalanine (FMLP) on gut permeability. A model of local inflammatory process.

Authors:  K E Magnusson; C Dahlgren; A Sjölander
Journal:  Inflammation       Date:  1985-12       Impact factor: 4.092

5.  Investigation of the endogenous chemoattractants involved in 111In-eosinophil accumulation in passive cutaneous anaphylactic reactions in the guinea-pig.

Authors:  V B Weg; M L Watson; L H Faccioli; T J Williams
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

6.  Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma.

Authors:  Marie-Chantal Larose; Anne-Sophie Archambault; Véronique Provost; Michel Laviolette; Nicolas Flamand
Journal:  Front Med (Lausanne)       Date:  2017-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.